865625-56-5

865625-56-5 structure

Name: Ladarixin sodium
Chemical Name: Sodium (1Z,2R)-N-(methylsulfonyl)-2-(4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)propanimidate
CAS Number: 865625-56-5
Molecular Formula: C₁₁H₁₁F₃NNaO₆S₂
Molecular Weight: 397.323
Catalog: Signaling Pathways GPCR/G Protein CXCR
Create Date: 2020-01-11 17:04:50
Modify Date: 2024-01-06 17:38:12
A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM; prevents PMN infiltration and tissue damage in several models of IR injury in vivo; abrogates motility and induces apoptosis in cultured cutaneous and uveal melanoma cells and xenografts; also prevents inflammation-mediated damage in MLD-STZ, prevents and reverses diabetes in NOD mice. Diabetes Phase 2 Clinical

Name	Sodium (1Z,2R)-N-(methylsulfonyl)-2-(4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)propanimidate
Synonyms	Methanesulfonic acid, 1,1,1-trifluoro-, 4-[(1R)-1-methyl-2-[(methylsulfonyl)amino]-2-oxoethyl]phenyl ester, sodium salt (1:1) Sodium (1Z,2R)-N-(methylsulfonyl)-2-(4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)propanimidate

Description	A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM; prevents PMN infiltration and tissue damage in several models of IR injury in vivo; abrogates motility and induces apoptosis in cultured cutaneous and uveal melanoma cells and xenografts; also prevents inflammation-mediated damage in MLD-STZ, prevents and reverses diabetes in NOD mice. Diabetes Phase 2 Clinical
References	References 1. Garau A, et al. Eur Cytokine Netw. 2006 Mar;17(1):35-41. 2. Citro A, et al. Diabetes. 2015 Apr;64(4):1329-40. 3. Kemp DM, et al. Oncotarget. 2017 Feb 28;8(9):14428-14442. 4. Bertini R, et al. Br J Pharmacol. 2012 Jan;165(2):436-54. View Related Products by Target Chemokine Receptor (CCR and CXCR) Diabetes